Shots: Tecentriq (atezolizumab, q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and […]readmore
Tags : PD-L1
Shots: The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 […]readmore
Shots: Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS […]readmore